血清基质金属蛋白酶2,9在心衰患者中的检测

The serum levels of matrix metalloproteinase2,9(MMP-2,9)in patients of heart failure

目的检测收缩性心衰及舒张性心衰患者和正常对照组血清中血清基质金属蛋白酶2,9的含量,探讨两种类型心衰与MMP-2,MMP-9表达的内在关系,从而进一步探讨MMP-2,MMP-9是否可作为心衰病情进展和评价心衰治疗效果及预后的新指标。方法酶谱方法检测81例心衰患者及20例正常对照组中血清中MMP-2,9的表达。结果SHF组及DHF组中MMP-2,MMP-9水平均明显高于对照组,差异均有统计学意义(P<0.05),而SHF组中MMP-9的增高水平高于DHF组,差异有统计学意义(P<0.05)且SHF2组MMP-2水平明显高于SHF1组。结论MMP-2可作为心衰的评判指标。

Objective To investigate the serum levels of expression of MMP-2 and MMP-9 in SHF, CHF and control groups respectively for the purpose of approaching the internal relationship between MMP-2, MMP-9 and CHF. Through the way, we could further study whether MMPs can be regarded as a new target to evaluate the progressing as well as the treatment and prognosis of CHF. Methods The expression of MMP-2 and MMP-9 were examined by SDS-PAGE zymograph in 40 SHF patients,40 DHF patients and 20 healthy people as control group. Results Compared with control group, both MMP-2 and MMP-9 were much higher in SHF and DHF groups（ all P 〈 0.05）. There is no evident difference about the level of MMP-2 in SHF and DHF groups（ P 〉 0.05）. However, in SHF gnoup, the level of MMP-2 in sever SHF group（SHFlgroup） is much higher than mild SHF group（SHF2group） （ P 〈 0.05）. Compared with DHF group, the level of MMP-9 was much higher in SHF group （ P 〈 0. 05）. Conclusion MMP-2 could be a index of evaluating the progressing of SHF.